Li Lulu, Tang Yue, Zhao Jinqi, Gong Lifei, Yang Nan, Wang Shunan, Yang Haihe, Kong Yuanyuan
Department of Newborn Screening Center, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Healthcare Hospital, Beijing, China.
Front Genet. 2024 Aug 12;15:1433160. doi: 10.3389/fgene.2024.1433160. eCollection 2024.
: The biochemical and genetic characteristics of four very-long-chain acyl-coenzyme A dehydrogenase deficiency (VLCADD) patients, clarifying their pathogenic genetic factors and evaluating the application value of genetic diagnosis in the early diagnosis of VLCADD, are reported and discussed in this article. : Patients underwent blood tandem mass spectrometry (MS/MS), urine gas chromatography (GC/MS), and high-throughput sequencing technology. New variants were analyzed for pathogenicity using bioinformatics software. Swiss-PdbViewer software was used to predict the effect of variants on the structure of the very-long-chain acyl-CoA dehydrogenase (VLCAD) protein. : A total of four VLCADD patients were diagnosed. They revealed elevated levels of C14, C14:1, C14:2, C14:1/C2, C14:1/C10, and C14:1/C12:1. Two patients were early-onset neonatal cases and died during infancy and the neonatal period, respectively. Seven kinds of variants were detected, including four novel variants. Bioinformatics software revealed that the variants were harmful, and the Swiss-PdbViewer results suggest that variation affects protein conformation. : This study identified four novel gene variants. These findings contribute to the understanding of the genetic basis and pathogenesis of VLCADD. Meanwhile, the study enriches the genetic mutation spectrum and the correlation between genotypes and phenotypes of VLCADD, indicating that genetic diagnosis plays an essential role in the early diagnosis and treatment of VLCADD.
本文报道并讨论了4例极长链酰基辅酶A脱氢酶缺乏症(VLCADD)患者的生化和遗传特征,明确了其致病基因因素,并评估了基因诊断在VLCADD早期诊断中的应用价值。患者接受了血液串联质谱(MS/MS)、尿液气相色谱(GC/MS)和高通量测序技术检测。使用生物信息学软件分析新变异的致病性。使用Swiss-PdbViewer软件预测变异对极长链酰基辅酶A脱氢酶(VLCAD)蛋白结构的影响。共诊断出4例VLCADD患者。他们的C14、C14:1、C14:2、C14:1/C2、C14:1/C10和C14:1/C12:1水平升高。2例为早发型新生儿病例,分别在婴儿期和新生儿期死亡。检测到7种变异,包括4种新变异。生物信息学软件显示这些变异有害,Swiss-PdbViewer结果表明变异影响蛋白质构象。本研究鉴定出4种新的基因变异。这些发现有助于理解VLCADD的遗传基础和发病机制。同时,该研究丰富了VLCADD的基因突变谱以及基因型与表型之间的相关性,表明基因诊断在VLCADD的早期诊断和治疗中起着至关重要的作用。